Outcome measures for clinical trials in paediatric IBD: An evidence-based, expert-driven practical statement paper of the paediatric ECCO committee

Gut

Volumn 64, Issue 3, 2015, Pages 438-446

  Ruemmele, Frank M ^a,b,c   Hyams, Jeffrey S ^d   Otley, Anthony ^e   Griffiths, Anne ^f   Kolho, Kaija Leena ^g   Dias, Jorge Amil ^h   Levine, Arie ⁱ   Escher, Johanna C ^j   Taminiau, Jan ^k   Veres, Gabor ^l   Colombel, Jean Frederic ^m   Vermeire, Séverine ⁿ   Wilson, David C ^o   Turner, Dan ^p  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b IMAGINE INSTITUTE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Division of Pediatric Infectious Diseases   (United States)

^e IWK HEALTH CENTRE   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF HELSINKI   (Finland)

^h HOSPITAL DE SÃO JOÃO   (Portugal)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^k EMMA CHILDREN S HOSPITAL   (Netherlands)

^l SEMMELWEIS UNIVERSITY   (Hungary)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o UNIVERSITY OF EDINBURGH   (United Kingdom)

^p HEBREW UNIVERSITY OF JERUSALEM   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; BIOLOGICAL MARKER;

ARTICLE; CHILD GROWTH; CLINICAL TRIAL (TOPIC); COLONOSCOPY; CONSENSUS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY SCORE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FISTULA; INTESTINE MUCOSA; INTESTINE ULCER; MAGNETIC RESONANCE ENTEROGRAPHY; MUCOSAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; QUALITY OF LIFE; RELAPSE; REMISSION; SCORING SYSTEM; STUDY DESIGN; ULCER HEALING; ULCERATIVE COLITIS; VULNERABLE POPULATION; BLOOD; CHILD; DELPHI STUDY; ENDOSCOPY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; PATHOLOGY; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

BIOMARKERS; CHILD; CLINICAL TRIALS AS TOPIC; DELPHI TECHNIQUE; ENDOSCOPY; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84922382262     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307008     Document Type: Article

References (99)

1. Pigneur B, Seksik P, Viola S., et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010; 16:953-61.
2. Van Limbergen J, Russell RK, Drummond H.E., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135:1114-22.
3. Karesh A, Tomaino J, Mulberg AE. Off-label use of medicine in pediatrics: focus on gastrointestinal diseases. Curr Opin Pediatr 2013; 25:612-17.
4. Froslie KF, Jahnsen J, Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-22.
5. Gustavsson A, Jarnerot G, Hertervig E., et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32:984-9.
6. Ardizzone S, Cassinotti A, Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9:483-9 e3.
7. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010; 16:1905-11.
8. Parente F, Molteni M, Marino B., et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010; 105:1150-7.
9. Danese S, Peyrin-Biroulet L. IBD: mucosal healing-EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 2012; 9:309-11.
10. Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol 2013; 47:212-21.
11. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142:1102-11 e2.
12. Travis SP, Schnell D, Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61:535-42.
13. Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013; 11:1460-5.
14. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 1985; 38:27-36.
15. Wright JG, Feinstein AR. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol 1992; 45:1201-18.
16. Marx RG, Bombardier C, Hogg-Johnson S, et al. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999; 52:105-11.
17. Aaronson N, Alonso J, Burnam A., et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11:193-205.
18. Irvine EJ, Feagan B, Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106:287-96.
19. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the nflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999; 13:65-73.
20. Yen JC, Abrahamowicz M, Dobkin P.L., et al. Determinants of discordance between patients and physicians in their assessment of lupus disease activity. J Rheumatol 2003; 30:1967-76.
21. Neville C, Clarke AE, Joseph L, et al. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 2000; 27:675-9.
22. Turner D, Griffiths AM, Mack D, et al. Assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis 2010; 16:651-6.
23. Feinstein AR. "Clinical Judgment" revisited: the distraction of quantitative models. Ann Intern Med 1994; 120:799-805.
24. Sands BE, Abreu MT, Ferry G.D., et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005; 11:S22-8.
25. Roth-Cline M, Gerson J, Bright P., et al. Ethical considerations in conducting pediatric research. Handb Exp Pharmacol 2011; 205:219-44.
26. Henderson P, Casey A, Lawrence S.J., et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107:941-9.
27. Kolho KL, Alfthan H, Hamalainen E. Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr 2012; 55:751-3.
28. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107:941-49.
29. Canani RB, Terrin G, Rapacciuolo L., et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008; 40:547-53.
30. Hanai H, Takeuchi K, Iida T., et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004; 49:1438-43.
31. D'Inca R., Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22:429-37.
32. Schoepfer AM, Beglinger C, Straumann A., et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15:1851-8.
33. Schoepfer AM, Beglinger C, Straumann A., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013; 19:332-41.
34. Turner D, Seow CH, Greenberg G.R., et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:1081-8.
35. van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012; 18:2018-25.
36. Kolho KL, Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN gastroenterol 2013; 2013:179024.
37. Kolho KL, Raivio T, Lindahl H., et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41:720-5.
38. Hamalainen A, Sipponen T, Kolho KL. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011; 17:5166-71.
39. Gerasimidis K, Nikolaou CK, Edwards C.A., et al. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011; 45:234-9.
40. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18:1894-9.
41. Griffiths AM, Nicholas D, Smith C., et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and BD type. J Pediatr Gastroenterol Nutr 1999; 28:S46-52.
42. Otley A, Smith C, Nicholas D., et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35:557-63.
43. Perrin JM, Kuhlthau K, Chughtai A., et al. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr 2008; 46:164-71.
44. Otley A. Measurement of quality of life in pediatric inflammatory bowel disease. In: Baldassano RN, Mamula P, Markowitz J, eds. Pediatric inflammatory bowel disease. Springer, 2008:565-80.
45. Ogden CA, Akobeng AK, Abbott J, et al. Validation of an instrument to measure quality of life in British children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:280-6.
46. Gray WN, Denson LA, Baldassano R.N., et al. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1581-6.
47. Griffiths AM, Otley AR, Hyams J, et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis 2005; 11:185-96.
48. Hyams JS, Griffiths A, Markowitz J., et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143:365-74 e2.
49. Hyams J, Crandall W, Kugathasan S., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863-73; quiz 1165-6.
50. Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis-lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis 2014; 8:1-4.
51. Efthymiou A, Viazis N, Mantzaris G., et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008; 14:1542-7.
52. Long MD, Barnes E, Isaacs K., et al. Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. Inflamm Bowel Dis 2011; 17:1855-62.
53. Lorenzo-Zuniga V, de Vega VM, Domenech E, et al. Impact of capsule endoscopy findings in the management of Crohn's Disease. Dig Dis Sci 2010; 55:411-14.
54. Hebuterne X, Lemann M, Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62:201-8.
55. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30:983-9.
56. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505-12.
57. Sipponen T, Nuutinen H, Turunen U., et al. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010; 16:2131-6.
58. Khanna R, Zou G, D'Haens G, et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. J Crohn's Colitis 2014; 8:S13-4.
59. Annese V, Daperno M, Rutter M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn's colitis 2013; 7:982-1018.
60. Hyams JS, Ferry GD, Mandel F.S., et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12:439-47.
61. Hyams J, Markowitz J, Otley A., et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41:416-21.
62. Turner D, Griffiths AM, Walters T.D., et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 2010; 105:2085-92.
63. Best WR, Becktel JM, Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-44.
64. Otley A, Loonen H, Parekh N., et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116:527-31.
65. Loonen HJ, Griffiths AM, Merkus M.P., et al. A critical assessment of items on the Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr 2003; 36:90-5.
66. Shepanski MA, Markowitz JE, Mamula P, et al. Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original?. J Pediatr Gastroenterol Nutr 2004; 39:68-72.
67. Kappelman MD, Crandall WV, Colletti R.B., et al. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis 2011; 17:112-17.
68. Turner D, Griffiths AM, Walters T.D., et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2011; 18:55-62.
69. Levine A, Turner D, Pfeffer Gik T, et al. Comparison of outcomes parameters for induction of remission in New Onset Pediatric Crohn's Disease: evaluation of the Porto IBD Group "Growth Relapse and Outcomes with Therapy" (GROWTH CD) Study. Inflamm Bowel Dis 2014; 20:278-85.
70. Panés J, Bouzas R, Chaparro M., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011; 34:125-45.
71. Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58:1113-20.
72. Rimola J, Ordas I, Rodriguez S., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011; 17:1759-68.
73. Neubauer H, Pabst T, Dick A., et al. Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. Pediatr Radiol 2013; 43:103-14.
74. Pazahr S, Blume I, Frei P., et al. Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience. MAGMA 2013; 26:291-301.
75. Horsthuis K, Lavini C, Bipat S., et al. Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity. Radiology 2009; 251:380-7.
76. Giles E, Barclay AR, Chippington S, et al. Systematic review: MRI enterography for assessment of small bowel involvement in paediatric Crohn's disease. Aliment Pharmacol Ther 2013; 37:1121-31.
77. Van Assche G, Vanbeckevoort D, Bielen D., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98:332-9.
78. Church P, Greer ML, Griffiths A, et al. United European Gastroenterol J 2013; 1 (Suppl 1):A51.
79. Pariente B, Cosnes J, Danese S., et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17:1415-22.
80. Quaia E, Migaleddu V, Baratella E., et al. The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn's disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment. Eur J Radiol 2009; 69:438-44.
81. Paredes JM, Ripolles T, Cortes X., et al. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. Dig Dis Sci 2010; 55:404-10.
82. Bailey. The Saskatchewan Pediatric Bone Mineral Accrual Study: bone mineral acquisition during the growing years. Int J Sports Med 1997; 18(SUPPL. 3): S191-4.
83. Turner D, Levine A, Escher J.C., et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55:340-61.
84. Turner D, Mack D, Leleiko N., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138:2282-91.
85. Turner D, Walsh CM, Benchimol E.I., et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008; 57:331-8.
86. Sylvester FA, Turner D, Draghi A II, et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis 2011; 17:1726-30.
87. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59:1207-12.
88. Turner D, Hyams J, Markowitz J., et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009; 15:1218-23.
89. Turner D, Schunemann HJ, Griffith L.E., et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010; 63:28-36.
90. Lee JJ, Colman RJ, Mitchell P.D., et al. Agreement between patient- and physician-completed Pediatric Ulcerative Colitis Activity Index scores. J Pediatr Gastroenterol Nutr 2011; 52:708-13.
91. Turner D, Travis SP, Griffiths A.M., et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106:574-88.
92. Sutherland LR, Martin F, Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92:1894-8.
93. Powell-Tuck J, Bown RL, Lennard-Jones JE.A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13:833-7.
94. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
95. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013; 11:49-54.e1.
96. Laharie D, Filippi J, Roblin X., et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013; 37:998-1004.
97. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013; 19:1194-201.
98. Bessissow T, Lemmens B, Ferrante M., et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012; 107:1684-92.
99. Colombel JF, Rutgeerts P, Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194-201.